Evaluation of aerosol drug delivery with concurrent low- and high-flow nasal oxygen

Barry Murphy, Marc Mac Giolla Eain, Mary Joyce, James B. Fink, Ronan MacLoughlin

Source: ERJ Open Res, 8 (4) 00220-2022; 10.1183/23120541.00220-2022
Journal Issue: October

Congress or journal article abstractFull text journal articlePDF journal article, handout or slides

Abstract

Question addressed by study

Administration of aerosol to patients receiving high-flow nasal oxygen (HFNO) ranges from concurrent aerosol delivery by mouthpiece to aerosol via cannula alone. This study examines the conditions to provide optimal aerosol delivery with low- or high-flow nasal oxygen with concurrent mouthpiece or through nasal cannula alone, and the impact on fugitive aerosols.

Materials and methods

A vibrating mesh nebuliser delivered salbutamol via mouthpiece, aerosol holding chamber and nasal cannula to an adult head model simulating relaxed breathing. The mean±sd inhaled dose (%) was assayed from a filter distal to the trachea. Optical particle sizers were used to measure fugitive aerosol concentrations during aerosol delivery.

Results

Concurrent low-flow nasal oxygen (LFNO) and aerosol delivery with a mouthpiece and aerosol holding chamber increased the inhaled dose (%) available, 31.44±1.33% when supplemented with 2 L·min-1 of nasal oxygen. Concurrent HFNO above 30 L·min-1 resulted in a lower inhaled dose (%) compared to aerosol delivered through HFNO alone. The addition of concurrent LFNO or HFNO resulted in no increase in aerosol levels in the test room.

Answer to question posed

Concurrent LFNO with a mouthpiece and aerosol holding chamber is an effective and safe means of aerosol delivery.



Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Barry Murphy, Marc Mac Giolla Eain, Mary Joyce, James B. Fink, Ronan MacLoughlin. Evaluation of aerosol drug delivery with concurrent low- and high-flow nasal oxygen. ERJ Open Res, 8 (4) 00220-2022; 10.1183/23120541.00220-2022

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.